July 15 (Reuters) - Investment funds Curi RMB Capital

and Oasis Management are contesting the pricing of Taisho

Pharmaceutical Holdings' ( TAIPY ) management buyout in court

after failed negotiations over their forced divestment as

minority shareholders, Nikkei newspaper reported on Monday.

Taisho's founding family gained 73% of the company in a

tender offer in January for 8,620 yen per share in a plan to

delist it. This was 55% more than the share price before the

offer was announced but still below Taisho's book value.

In March, Oasis said it was considering legal action over

Taisho's $5 billion management buyout - Japan's largest to date

- arguing that it was deeply unfair to minority shareholders.

Curi RMB, which did not tender its stake in Taisho, faced a

forced divestment. In February, it said "the tender offer price

was set at an unfairly low price, which is not in the best

interest of minority shareholders."

Oasis Management has also cited concerns over Taisho's

special committee's functioning and raised the likelihood that

the value of Taisho Pharma's property holdings and strategic

shareholdings were not properly reflected, the report added.

Taisho Pharma could not immediately be reached for a

comment. Oasis and Curi RMB did not immediately respond to

requests for comment.